MarketsandMarkets Next-Gen Bioprocessing Global Virtual Conference

Devising Effective Manufacturing & Quality Control Methods of Cell Therapies

Over the last 50 years, the bioprocessing industry has witnessed tremendous change, overcoming many challenges to increase efficiency and productivity throughout the development and manufacturing process. These efforts have been particularly focused to elicit major advancements for cell lines, culture media, and downstream processes used to produce therapeutics.

MarketsandMarkets is extremely delighted to announce its “ MarketsandMarkets Next-Gen Bioprocessing Virtual Conference” scheduled to be held on 6th- 7th October 2022. The conference is designed for having interactive discussions in cell culture, scale-up, continuous biomanufacturing, recovery, purification, process and product characterization, formulation, case studies in analytics and stability. The conference also includes interactive breakout sessions, solutions and services supporting the rapidly growing bioprocessing industry. The event will witness the participation of decision makers from the pharmaceutical industry who are shaping the future of the bioprocessing industry.

Key Highlights

CELL CULTURE & BIOPRODUCTION

Protein synthesis and cell line development
Bioproduction 4.0
Bioprocess development strategies
Process monitoring and control
Bioproduction innovations

DOWNSTREAM PROCESSING & CONTINUOUS BIOMANUFACTURING

Upstream and downstream process optimization
Enhancing protein purification
Biomanufacturing 2030: The latest manufacturing shift
Pharma 4.0 trends and new drug delivery strategies
Commercial manufacturing case studies

CELL AND GENE THERAPY ANALYTICS & MANUFACTURING

Cell & Gene therapy analytics and characterization
Emerging analytical methods & Quality Control
AAV scale-up and manufacturing
Cell & Gene therapy process development
Navigating cell & gene therapy CMC and comparability

Who Should Attend?

CEO’s, CSO’s, COO’s, Presidents, Vice Presidents, Directors, Investigators, Heads, Managers, Principal scientists, Scientists, Professors, Lecturers, Group Heads & Researchers

From Pharmaceuticals/Therapeutics/Cell-Gene therapy-based companies.
Academics: Universities/ Research Labs/Research Institutes

• Working on:

Bioprocess development
Process development
GMP/Manufacturing
Cellular Therapy
Gene Therapy
Quality Control
Cell Engineering
Scale up Bioprocessing
Scale down bioprocessing
Fermentation
Cell Therapy
Cell culture operations
mRNA type therapeutics
ATMP (Advanced therapy medicinal products)
CAR T-cell therapy
Monoclonal antibodies (mAbs)
Viral vectors

Why Attend ?

Participate in discussions with experts on how technology implementation can be improved
Attracting and retaining world-class pharma and biotech talent
Improve the efficiency of bio-manufacturing by engaging in environmentally sustainable methods
Resolve common contamination and R&D challenges
Discover the latest technology implementations in the industry
Discover best-in-class solutions during the workshop sessions
Interactive panel discussions

MarketsandMarkets Next-Gen Bioprocessing Global Virtual Conference (Time zone: CET)

Devising Effective Manufacturing & Quality Control Methods of Cell Therapies

Key Highlights

Who Should Attend?

Why Attend ?

Welcome note from MarketsandMarkets

Opening Remarks from the Chairperson

Keynote Presentation – Making CAR-T cell therapies affordable to the Indian sub-continent

CAR T-cell immunotherapy of solid tumors: Parallel learning from the clinic and lab

Role of Cellular Post Translational Modifications in Regulating Growth and Productivity of Recombinant Chinese Hamster Ovary Cells

Antibody-targeted lipid-nanoparticle mediated inhibition of the GPCR RXFP1 signaling pathway as a therapeutic approach for ovarian cancer

Microfluidics in the delivery of biologics

Closing Remarks from the Chairman

Welcome note from MarketsandMarkets

Opening Remarks from the Chairman

Keynote Presentation- Apheresis Collections in Cell & Gene Therapy

A convenient self-removing affinity tag to streamline biopharmaceutical discovery through manufacturing

Analytical Development for Extracellular Vesicles

Microproteins are a new class of potential host cell impurity in monoclonal antibody (mAb) drug products

Scalable manufacturing of ex vivo gene therapy product using human mesenchymal stromal cells (hMSCs)

Closing Remarks from the Chairperson

End of Conference